^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non Small Cell Lung Cancer
    Drug:cisplatin (DNA synthesis inhibitor) +
    pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    02/08/2020
    Excerpt:
    PEMFEXY is a folate analog metabolic inhibitor indicated...in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non squamous, non-small cell lung cancer (NSCLC).
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    11/26/2015
    Excerpt:
    Pemetrexed medac in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Non-Small Cell Lung Cancer: Useful in Certain Circumstances...Cisplatin/pemetrexed...
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    J Clin Oncol
    Title:

    Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

    Excerpt:
    Overall survival for cisplatin/pemetrexed was noninferior to cisplatin/gemcitabine (median survival, 10.3 v 10.3 months, respectively; HR = 0.94; 95% CI, 0.84 to 1.05)....In advanced NSCLC, cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cisplatin/gemcitabine.
    DOI:
    10.1200/JCO.2007.15.0375